Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lymphoma Clinical Trials in Minneapolis | 229 Studies

Clinical Trials LymphomaMinneapolis

Lymphoma Clinical Trials in Minneapolis

Find 229 clinical trials for lymphoma near Minneapolis, Minnesota. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Minneapolis

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 201-220 of 229 trials

CompletedEfficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaTo evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab…NCT02285062·Fayetteville, Arkansas and 157 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedMyeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesRATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the…NCT00309842·Minneapolis, Minnesota and 1 other

CompletedStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaThe primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with…NCT02625480·Los Angeles, California and 29 others

TerminatedReduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesThis is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen.NCT02145039·Minneapolis, Minnesota

Active not recruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialThis phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to…NCT04320888·Birmingham, Alabama and 173 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00002941·Birmingham, Alabama and 234 others

TerminatedA Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaThe purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL).NCT04860466·Minneapolis, Minnesota and 12 others

CompletedPh I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLThis is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients…NCT03019666·Minneapolis, Minnesota

RecruitingTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaThis phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated…NCT04840602·Tucson, Arizona and 149 others

CompletedStudy of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationBackground: \- In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient.NCT02356159·Bethesda, Maryland and 1 other

CompletedA Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaThis is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia.NCT02723994·Birmingham, Alabama and 110 others

CompletedTraumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell TransplantationRATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem…NCT00080873·Birmingham, Alabama and 43 others

TerminatedStudy of Immune Response Modifier in the Treatment of Hematologic MalignanciesThe purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.NCT00276159·Minneapolis, Minnesota

CompletedTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that…NCT03213665·Birmingham, Alabama and 116 others

CompletedAzacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene RearrangementThis pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.NCT02828358·Birmingham, Alabama and 169 others

TerminatedPhase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLAFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts.NCT05883449·Birmingham, Alabama and 14 others

CompletedEtoposide in Treating Patients With Relapsed Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00002880·Minneapolis, Minnesota and 3 others

CompletedBortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaThis phase II trial studies how well bortezomib and lenalidomide work in treating patients with mantle cell lymphoma that has come back after a period of improvement (refractory)…NCT00553644·Anaheim, California and 81 others

WithdrawnAlemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerRATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer…NCT00085449·La Jolla, California and 23 others

TerminatedPhase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's LymphomaThe purpose of this study is to determine the optimal dose of Campath for patients with relapsing or refractory (failed standard therapy) non-Hodgkin's lymphoma.NCT00051701·Aurora, Colorado and 16 others

PreviousPage 11 of 12Next

Other Conditions in Minneapolis

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia